FDA Expands Urticaria Drug Indication to Symptomatic Dermographism
The FDA has expanded a urticaria drug's indication to treat symptomatic dermographism, moving a common inducible urticaria into on-label treatment territory.
Topic
Symptomatic Dermographism
Topic
Symptomatic Dermographism
FDA Approves Remibrutinib for Symptomatic Dermographism
The US FDA has approved oral BTK inhibitor remibrutinib for symptomatic dermographism, delivering the first labeled targeted ther…